



Please review the Supplemental Files folder to review documents not compiled in the PDF.

## Interferon Beta-1a ring prophylaxis to reduce household transmission of SARS-CoV-2

Journal:	<i>New England Journal of Medicine</i>
Manuscript ID	Draft
Article Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Castro-Rodriguez, Jose; Pontifical Catholic University of Chile, Pediatrics                      Fish, Eleanor; Toronto General Research Institute, University Health Network; University of Toronto, Immunology                      Kollmann, Tobias; Telethon Kids Institute; Perth Children's Hospital, Infectious Diseases                      Iturriaga, Carolina; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology                      Karpievitch, Yulia; Telethon Kids Institute; The University of Western Australia, School of Biomedical Sciences                      Shannon, Casey; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation                      Chen, Virginia; The University of British Columbia Faculty of Science; The University of British Columbia Centre for Heart Lung Innovation                      Balshaw, Robert; University of Manitoba College of Medicine, George and Fay Yee Centre for Healthcare Innovation                      Ben Othman, Rym; Telethon Kids Institute                      Montgomery, Samuel; Telethon Kids Institute,                      Aniba, Radhouana; Telethon Kids Institute                      Ho, Joseph; Telethon Kids Institute                      Gidi-Yunge, Fancisca; Pontifical Catholic University of Chile, School of Dentistry                      Hartnell, Lucy; Telethon Kids Institute                      Perez-Mateluna, Guillermo; Pontifical Catholic University of Chile, Department of Pediatric Infectious Diseases and Immunology                      Urzúa, Marcela; Pontifical Catholic University of Chile, Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina                      Tebbutt, Scott; UBC; The University of British Columbia Centre for Heart Lung Innovation                      Garcia-Huidobro, Diego; Pontifical Catholic University of Chile, Department of Family Medicine; University of Minnesota Twin Cities, Department of Family Medicine and Community Health                      Perret, Cecilia; Pontifical Catholic University of Chile, Pediatric Infectious Diseases and Immunology                      Borzutzky, Arturo; Pontificia Universidad Católica de Chile, Pediatric Infectious Diseases and Immunology                      Stick, Stephen; Telethon Kids Institute, Wal-yan Respiratory Research Centre; The University of Western Australia, Centre for Child Health Research; Perth Children's Hospital, Respiratory and Sleep Medicine</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Abstract:	<p><b>Background</b> Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding. Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFN<math>\beta</math>-1 could reduce SARS-CoV-2 household transmission.</p> <p><b>Methods</b> A household cluster randomized controlled study of IFN<math>\beta</math>-1 administered to non-hospitalized, symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years compared to standard care, was conducted. Following randomization participants received IFN<math>\beta</math>-1 on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary polymerase chain reaction measurements until day 29 in both study arms. A post-hoc 'at risk population' was defined as households where the index case was positive at the start of the study and there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2. Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i) reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household contacts.</p> <p><b>Results</b> In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive IFN<math>\beta</math>-1 and 565 to standard care. Based on intention to treat and per protocol analyses, IFN<math>\beta</math>-1 treatment was ineffective. However, in the 'at risk' population, the relative risk of infection was reduced by 23% in treated individuals and that there was a 95% probability that IFN<math>\beta</math>-1 reduced household transmission.</p> <p><b>Conclusion</b> Ring prophylaxis with IFN<math>\beta</math>-1 reduces the probability of SARS-CoV-2 transmission within a household.</p>



## Interferon Beta-1 $\alpha$ ring prophylaxis to reduce household transmission of SARS-CoV-2

### Authors

José A. Castro-Rodriguez, PhD  
Pontifical Catholic University of Chile

Eleanor N. Fish PhD  
University of Toronto

Tobi Kollmann PhD  
Telethon Kids Institute

Carolina Iturriaga, RN  
Pontifical Catholic University of Chile

Yuliya Karpievitch PhD  
Telethon Kids Institute

Casey Shannon BSc  
Prevention of Organ Failure (PROOF) Centre of Excellence

Virginia Chen BSc  
Prevention of Organ Failure (PROOF) Centre of Excellence

Robert Balshaw PhD  
Centre for Healthcare Innovation, University of Manitoba

Samuel Montgomery PhD  
Telethon Kids Institute

Joseph Ho, MSc  
Telethon Kids Institute

Rym Ben Othman, PhD  
Telethon Kids Institute

Radhouana Aniba, PhD  
Telethon Kids Institute

Francisca Gidi-Yunge, DDS  
Pontifical Catholic University of Chile

Lucy Hartnell, MSc  
Telethon Kids Institute

Guillermo Pérez-Mateluna, Biotech  
Pontifical Catholic University of Chile

Marcela Urzúa, RN  
Pontifical Catholic University of Chile

Scott Tebbutt, PhD  
Prevention of Organ Failure (PROOF) Centre of Excellence

Diego García-Huidobro, PhD  
Pontifical Catholic University of Chile

Cecilia Perret, MD  
Pontifical Catholic University of Chile

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Arturo Borzutzky, MD  
2 Pontifical Catholic University of Chile

3 Stephen M. Stick, PhD  
4 Telethon Kids Institute

5  
6 **Corresponding author:** Professor Stephen Stick  
7 stephen.stick@health.wa.gov.au

Confidential: For Review

1  
2 **1 Abstract (words 250)**

3  
4 **2**  
5 **3 Background**

6  
7 **4** Evidence suggests that early, robust type 1 interferon responses to SARS-CoV-2 are critical  
8  
9 **5** determinants for COVID-19 disease outcomes, accelerating viral clearance and limiting viral shedding.  
10  
11 **6** Accordingly, we undertook a ring prophylaxis study to determine whether pegylated IFN $\beta$ -1 $\alpha$  could  
12  
13 **7** reduce SARS-CoV-2 household transmission.

14  
15  
16  
17 **8 Methods**

18  
19 **9** A household cluster randomized controlled study of IFN $\beta$ -1 $\alpha$  administered to non-hospitalized,  
20  
21 **10** symptomatic COVID-19 index cases and treatment-eligible household contacts aged 18-70 years  
22  
23 **11** compared to standard care, was conducted. Following randomization participants received IFN $\beta$ -1 $\alpha$   
24  
25 **12** on days 1, 6, and 11 or standard care. Viral shedding was determined by sequential salivary  
26  
27 **13** polymerase chain reaction measurements until day 29 in both study arms. A post-hoc ‘at risk  
28  
29 **14** population’ was defined as households where the index case was positive at the start of the study and  
30  
31 **15** there was at least one treatment eligible contact in a household who tested negative for SARS-CoV-2.  
32  
33 **16** Frequentist and Bayesian analyses were undertaken to determine the effects of treatment on (i)  
34  
35 **17** reducing viral shedding in index cases and (ii) reducing viral transmission to post-exposure household  
36  
37 **18** contacts.  
38  
39  
40  
41  
42

43  
44 **19 Results**

45  
46 **20** In total, 1172 participants in 341 households underwent randomization, with 607 assigned to receive  
47  
48 **21** IFN $\beta$ -1 $\alpha$  and 565 to standard care. Based on intention to treat and per protocol analyses, IFN $\beta$ -1 $\alpha$   
49  
50 **22** treatment was ineffective. However, in the ‘at risk’ population, the relative risk of infection was  
51  
52 **23** reduced by 23% in treated individuals and that there was a 95% probability that IFN $\beta$ -1 $\alpha$  reduced  
53  
54 **24** household transmission.  
55  
56  
57  
58  
59  
60

1  
2 1 Conclusion  
3  
4 2 Ring prophylaxis with IFN $\beta$ -1 $\alpha$  reduces the probability of SARS-CoV-2 transmission within a  
5  
6  
7 3 household.  
8

9 4  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review

1  
2 **1 Introduction (Words 3284)**  
3

4 2 The SARS-CoV-2 pandemic has claimed over six million lives. Despite the rapid development and  
5  
6 deployment of vaccines in many countries, the number of new cases worldwide still exceeds 500,000  
7 3  
8 daily (<https://covid19.who.int>). With each wave of the pandemic, health systems have been  
9 4  
10 challenged and the likelihood of emergence of mutant strains of the virus remains. Mutated strains  
11 5  
12 may be more transmissible <sup>1,2</sup>, cause more severe disease than the original pandemic strain of SARS-  
13  
14 CoV-2 <sup>3</sup> and have the potential to evade available vaccines <sup>4,5</sup>. Whilst widespread vaccination has had  
15  
16 success limiting the trajectory of the pandemic, the emergence of the omicron variants demonstrated  
17 7  
18 that even with mutations that appear to cause less severe disease <sup>6</sup>, high transmission despite  
19 8  
20 immunization could still result in significant pressures on health services <sup>7</sup>.  
21 9  
22  
23  
24 10

25  
26  
27 11  
28 12 The solution to halting any pandemic is ending community transmission. During the current  
29  
30 pandemic, measures such as healthy hygiene, self-isolation when sick, physical-distancing and use of  
31 13  
32 facemasks have all been effective <sup>8</sup>. Moreover, expedited public health responses such as extensive  
33 14  
34 contact-tracing, testing for infection and community lockdowns have all been effective methods to  
35 15  
36 curb transmission <sup>9</sup>. International and local border closures plus strict quarantine measures have  
37  
38 reduced community transmission to zero for periods in countries such as Australia and New Zealand  
39  
40 <sup>10,11</sup>. However, in these countries and elsewhere, as restrictions are relaxed, localized outbreaks have  
41 17  
42 occurred <sup>12</sup> that have required rapid, community-wide responses to again suppress transmission.  
43 18  
44  
45 19 Importantly, these community constraints cause unprecedented civil disruption and come at  
46  
47 enormous economic <sup>13,14</sup> and social costs <sup>15,16</sup>.  
48 20  
49  
50 21

51  
52 22  
53  
54  
55 23  
56  
57  
58  
59  
60

1  
2 1 Since the evolution of dominant SARS-CoV-2 virus cannot be easily predicted<sup>17</sup>, there remains a need  
3  
4 2 to identify interventions that can be rapidly deployed should highly pathogenic strains emerge despite  
5  
6  
7 3 high levels of community immunization. Furthermore, preparations for the next pandemic must  
8  
9 4 include strategies to limit the potential for infection and transmission on first contact with pathogenic  
10  
11  
12 5 respiratory viruses.

13  
14 6  
15  
16 7 One of the many therapeutic approaches investigated that appeared clinically useful early in the  
17  
18  
19 8 course of the pandemic was treatment with type 1 interferons (IFNs). Randomized, controlled studies  
20  
21  
22 9 suggest that IFNs offer clinical benefits in moderate<sup>18</sup> and severe disease<sup>19,20</sup> }, reduce the duration  
23  
24 10 of viral shedding<sup>21</sup> and prevent infection in front-line hospital workers<sup>22</sup>. Nonetheless, IFNs are not  
25  
26  
27 11 generally recommended for treatment of proven cases of Covid-19<sup>23</sup>.

28  
29 12  
30  
31 13 Since IFNs are sentinel innate immune signalling molecules produced early after first contact with viral  
32  
33  
34 14 pathogens<sup>24-26</sup>, we postulated that prophylactic IFN treatment might reduce susceptibility to infection  
35  
36 15 of uninfected contacts of individuals with SARS-CoV-2 infection. Such post-exposure prophylaxis could  
37  
38  
39 16 provide non-specific, antiviral protection to curb episodic viral outbreaks<sup>27</sup>, help suppress community  
40  
41 17 transmission, even in vaccinated populations, and therefore reduce the risk of emergence of  
42  
43  
44 18 dangerous mutations<sup>4,28</sup>.

45  
46 19  
47  
48 20 We therefore undertook a cluster, randomized, controlled study of sub-cutaneous pegylated IFN $\beta$ -1 $\alpha$   
49  
50  
51 21 (Plegridy. Biogen Inc, Cambridge MA) administration to determine whether IFN $\beta$ -1 $\alpha$  therapy given to  
52  
53  
54 22 index cases and household contacts can reduce transmission of SARS-CoV-2.  
55

56 23  
57  
58  
59  
60  
Confidential: Destroy when review is complete.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Methods**

2 The Containing Coronavirus Disease-19 (ConCorD-19) trial was a prospective,  
3 cluster, randomized trial of subcutaneous (sc) administration of pegylated IFN $\beta$ -1 $\alpha$  (Plegridy, Biogen  
4 Inc, Switzerland) versus standard care (control) <sup>29</sup>. Each household of an index case was randomized  
5 to either the IFN $\beta$ -1 $\alpha$  treatment or the standard care control arm. The study was approved by the  
6 Institutional Review Board of the Pontificia Universidad Católica de Chile and was registered with  
7 clinicaltrials.gov (NCT04552379). All participants provided written informed consent.

9 *Trial population*

10 Index cases were identified from databases of those with confirmed SARS-CoV-2 from COVID-19  
11 clinics and emergency room visits in Santiago, Chile. Households were contacted by telephone to  
12 determine eligibility prior to enrolment. Individuals aged between 18 and 80 years who met inclusion  
13 and exclusion criteria were deemed as 'eligible' contacts with households only included if there was at  
14 least one eligible contact <sup>29</sup>. Enrolment and the first doses of IFN $\beta$ -1 $\alpha$  - if in the intervention arm- had  
15 to be within 72 hours of the positive identification of SARS-CoV-2 by polymerase chain reaction (PCR)  
16 in index cases. A household was excluded if the index case had been in complete self-quarantine  
17 from other household members during the 48 hours prior to the diagnosis of SARS-CoV-2 infection <sup>29</sup>.  
18 Household characteristics were captured consistent with recommendations of the World Health  
19 Organization for assessing household transmission <sup>30</sup>. All participants implemented quarantine  
20 measures as mandated by local authorities and maintained a daily symptom diary which was collected  
21 and reviewed at each study visit by the study team (see online supplementary material). At any time  
22 during the trial, if a contact participant developed symptoms suggestive of COVID-19, a  
23 nasopharyngeal swab was taken by a member of a mobile health team for virus PCR testing in an

1  
2 1 accredited SARS-CoV-2 diagnostic laboratory. Index cases were instructed to remain in isolation /  
3  
4 2 quarantine for 11 days from onset of symptoms or, if asymptomatic, 11 days from the  
5  
6  
7 3 sample collection date that resulted in the COVID-19 diagnosis. Household contacts remained in  
8  
9 4 isolation / quarantine for 11 days from date of the sample resulting in the diagnosis of the index case  
10  
11  
12 5 or of a newly diagnosed household member as per recommendations/rulings by local authorities.

### 13 14 6 15 16 7 *Intervention*

17  
18  
19 8 A mobile health team conducted home visits of all participant households on study days 1  
20  
21 9 (enrolment), 6, 11, 16 and 29. Index cases and eligible household contacts in the IFN $\beta$ -1 $\alpha$  arm  
22  
23  
24 10 received three subcutaneous doses of pegylated IFN $\beta$ -1 $\alpha$  (125 $\mu$ g/0.5ml x 0.5ml) on study days 1, 6  
25  
26  
27 11 and 11. Ineligible contacts in the IFN $\beta$ -1 $\alpha$  arm, as well as index cases and all household contacts in  
28  
29 12 the SOC arm, received standard care. All participating households received information regarding  
30  
31  
32 13 hygiene, isolation, social distancing and wearing of facemasks as per public health advice at the time  
33  
34 14 of enrolment. The IFN $\beta$ -1 $\alpha$  injection was given by a trained member of a mobile health team and  
35  
36  
37 15 participants were recommended to take paracetamol (1000mg, 6 hourly) commencing at the same  
38  
39 16 time as the IFN $\beta$ -1 $\alpha$  for up to twenty-four hours, in order to mitigate predictable flu-like symptoms  
40  
41 17 <sup>31</sup>.

### 42 43 44 18 45 46 19 *Outcomes*

47  
48  
49 20 The primary outcomes were (i) the proportion of index cases shedding SARS-CoV-2 at study day 11 in  
50  
51 21 the IFN $\beta$ -1 $\alpha$  compared to control arm and (ii) the proportion of household contacts shedding SARS-  
52  
53  
54 22 CoV-2 at day 11, in the IFN $\beta$ -1 $\alpha$  compared to the control arm. Secondary and exploratory outcomes  
55  
56 23 are listed in Supplementary Methods (Supplementary Table 1). Shedding was determined by the

1  
2 1 presence of SARS-CoV-2 by PCR in saliva collected on days 1, 6, 11, 16, 21, and 29 (see Supplementary  
3  
4 2 Methods). A SARS-CoV-2 PCR Ct value  $\geq 40$  was considered negative. Viral load was estimated from  
5  
6  
7 3 the Ct value using a standard algorithm (Supplementary Figure 1  
8

#### 9 4 10 11 5 *Biospecimen collections*

12 6 The full schedule of biospecimen collection is provided in the supplementary methods  
13  
14 7 (Supplementary Tables 2 and 3. All consenting, non-eligible household contacts also provided  
15  
16  
17 8 biospecimens according to the schedule collection for non-eligible household contacts.  
18  
19  
20  
21  
22 9

#### 23 24 10 *Adverse events*

25  
26 11 These were classified in accordance with Good Clinical Practice <sup>32</sup>, as non-serious or serious and as  
27  
28  
29 12 related or unrelated to the trial medication.  
30  
31  
32  
33

#### 34 14 *Statistical considerations*

35  
36 15 The study was designed at the start of the pandemic and there were few data to guide sample size  
37  
38  
39 16 calculations. We therefore planned both frequentist inference and Bayesian analyses based on  
40  
41 17 assumptions from the available data.  
42  
43  
44 18

45  
46 19 Households were randomized as individual clusters using a minimization technique (biased coin,  
47  
48 20  $P=0.7$ ) in order to achieve balance between treatment arms, stratified by the number of people within  
49  
50  
51 21 the household <sup>33</sup>.  
52  
53  
54 22  
55  
56  
57  
58  
59  
60

1  
2 1 Sample size calculations assumed,  $\alpha=0.025$  and power 90%, a zero correlation between outcome  
3  
4 2 measures and that the household-wise, type 1 error rate would be below 0.05 and power above 80%.  
5  
6  
7 3 The estimated average household size was 4, based on census data <sup>34</sup>.

8  
9 4  
10  
11  
12 5 Primary outcomes:

13  
14 6 (i) SARS-CoV-2 shedding at study day 11 by index cases: Data from Wuhan suggested that the  
15  
16 7 proportion of untreated index cases still shedding virus on study day 11 would be ~85% <sup>35</sup>. Based on a  
17  
18 8 two tailed Fisher's exact test, a sample size of 278 index cases (139 per arm) would have 90% power  
19  
20 9 to detect a difference in the proportion of individuals shedding virus at study day 11, if the proportion  
21  
22 10 in the IFN $\beta$ -1 $\alpha$  arm was 65%.

23  
24  
25  
26 11  
27  
28  
29 12 (ii) SARS-CoV-2 shedding at study day 11 by household contacts: We estimated the secondary  
30  
31 13 infection rate (transmission within the household) where there is an untreated index case would  
32  
33 14 be 28% <sup>36,37</sup>. Based on a stratified Cochran-Mantel-Haenszel test (two-tailed with intra-class  
34  
35 15 correlation of 0.15), we estimated that a sample of 278 households (834 eligible household contacts)  
36  
37 16 would have >90% power, at alpha 0.025, to detect an odds ratio of 0.5 for a reduction in transmission  
38  
39 17 to a treated household contact.

40  
41  
42  
43 18  
44  
45  
46 19 Based on these assumptions and estimates, we aimed to recruit 310 households (allowing for a 10%  
47  
48 20 drop-out rate) and 930 eligible household contacts.

49  
50  
51 21  
52  
53 22 We undertook 3 separate sets of analyses:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(A) Standard frequentist analyses based on the primary outcomes as stated in the protocol and described in the Statistical Analysis Plan (available online) and included intention to treat and per protocol approaches .

(B) Exploratory frequentist analyses based on a modified dataset that accounted for biological implausibility and effects that might only be associated with active treatment (Figure 1 and Supplementary Table 1 for further explanations).

Both frequentist analyses fitted linear mixed effects models using lme4<sup>38</sup> (see Statistical Analysis Plan).

(C) Exploratory Bayesian analyses using the same dataset as the exploratory frequentist analysis. Detailed methods are provided in the supplementary methods. Briefly, a generalized linear model with mixed effects was developed to estimate the probability of infection that is influenced by explanatory variables for each contact case. A stan\_glm with binomial logit function in rstanarm R package was used<sup>39,40</sup>.

The frequentist approach allowed us to estimate the effects of IFN $\beta$ -1 $\alpha$  treatment on the risk of an *individual* becoming infected. Whereas the Bayesian analysis allowed us to determine whether the ring prophylaxis strategy using IFN $\beta$ -1 $\alpha$  reduces the probability of transmission within the household of an infected index case.

With regard to the filtered datasets, we observed, after locking the database, that a number of index cases had negative PCR results on the day of recruitment despite a previous positive diagnostic PCR test. In the exploratory analyses we therefore excluded households where the index case was unlikely to transmit virus because they were not shedding virus on days 1 and day 6 of the study. We

1  
2 1 also excluded households where an eligible contact was already positive at recruitment and there  
3  
4 2 were no other eligible negative cases in the household. We refer to the modified dataset as the  
5  
6 3 population "at risk". We used the population at risk data to better understand the effects of IFN $\beta$ -1 $\alpha$   
7  
8 4 treatment on transmission of virus within households.  
9  
10

11  
12 5  
13  
14 6 When undertaking these exploratory analyses, we considered effects during two time periods. Days  
15  
16 7 1-11 (Period 1) i.e., the treatment and isolation period when eligible contacts in the IFN $\beta$ -1 $\alpha$  arm  
17  
18 8 were likely to have elevated IFN levels based on the known pharmacokinetics of pegylated IFN $\beta$ -1 $\alpha$   
19  
20 9 and days 12-29 (Period 2) the post-treatment and isolation period when biological effects of  
21  
22 10 pegylated IFN $\beta$ -1 $\alpha$  were likely to be waning in treated individuals. Although samples were not  
23  
24 11 obtained on days 12-15, we assumed that anyone who became infected during this period would  
25  
26 12 likely still to have a positive PCR on day 16.  
27  
28  
29  
30

## 31 13 32 33 34 14 **Results**

35  
36 15 Recruitment, participation, and completion data are shown in Figure 1. Participant demographic and  
37  
38 16 basic household characteristics data are shown in Table 1.  
39  
40

41 17  
42  
43  
44 18 Between December 2020 and May 2021, three-hundred and forty-one households were enrolled and  
45  
46 19 randomized, of which 137 (IFN $\beta$ -1 $\alpha$  arm) and 151 (control arm) completed the study. Of the 1172  
47  
48 20 individuals randomized (IFN $\beta$ -1 $\alpha$  arm = 607; Controls = 565), 53 individuals withdrew from the study,  
49  
50 21 of which 15 were index cases; 35 (14 index cases) in the IFN $\beta$ -1 $\alpha$  arm and 18 (1 index case) in the  
51  
52 22 control arm. The reasons for withdrawal are summarized in the supplementary results  
53  
54 23 (Supplementary Table 4). One index case withdrew before being allocated to a treatment arm.  
55  
56  
57  
58  
59  
60

1  
2 1  
3  
4 2 Eighty-two households where the index case had a negative salivary PCR on Day 1 and 6, or where  
5  
6  
7 3 there were no eligible contacts who tested negative at recruitment, were excluded from the  
8  
9 4 exploratory analyses. The remaining households were considered as the 'at risk' population. (Figure  
10  
11 1).

12 5  
13  
14 6  
15  
16 7 *(a) Primary analyses*

17  
18  
19 8 The outcomes for the intention to treat (ITT) and per protocol (PP) frequentist analyses were similar  
20  
21 9 (Supplementary Results). There was no effect of IFN $\beta$ -1 $\alpha$  treatment on duration of viral shedding in  
22  
23  
24 10 those treated (index cases or infected contacts) vs. controls (IC-INF: treatment OR = 0.979, 95%CI =  
25  
26 11 0.647 to 1.479); IC-ITT: treatment OR = 1.106, 95%CI = 0.657 to 1.863); IC-PP: treatment OR = 1.062,  
27  
28  
29 12 95%CI = 0.622 to 1.810); Figure 2A). The observed reduction in transmission to household contacts  
30  
31 13 associated with IFNbeta-1alpha by day 11 was not significant (EHC-ITT: treatment OR = 0.582, 95%CI  
32  
33  
34 14 = 0.271 to 1.247; HC: treatment OR = 0.577, 95%CI = 0.287 to 1.160; EHC-PP: treatment OR = 0.589,  
35  
36 15 95%CI = 0.272to 1.276; Figure 2B). Vaccination status did not affect these outcomes (Supplementary  
37  
38  
39 16 results).

40  
41 17 *(b) Exploratory frequentist analysis of 'At Risk Population.'*

42  
43 18 Of the at risk population, 33/164 (20%) in the IFN $\beta$ -1 $\alpha$  arm became infected by day 29 of the study  
44  
45  
46 19 compared to 37/142 (26%) in the control arm (relative risk reduction in the IFN arm = 23%). The  
47  
48  
49 20 majority of the risk reduction occurred during the active treatment phase of the study (days 1 to 11).  
50  
51 21 Treatment with IFN $\beta$ -1 $\alpha$  was associated with a significant reduction in the odds of a positive saliva  
52  
53 22 PCR for all household contacts compared to standard of care on Day 11 ( $p$  = 0.033; OR = 0.550, 95% CI  
54  
55  
56  
57  
58  
59  
60

1  
2 1 = 0.364 to 0.989). The treatment effect was not significant in the second period (days 12-29) was  
3  
4 2 not significant (OR = 0.968, 95% CI = 0.405 to 2.840) (Figure 2C)  
5  
6

7 3  
8  
9 4 *(c) Exploratory Bayesian analysis:*  
10

11 5 Overall, there was a 95% probability of infection reduction within a household by IFN $\beta$ -1 $\alpha$  treatment  
12 6 and the credible interval for the reduction in transmission probability was in the order of 0.9 to  
13  
14 7 15.9%. During the active treatment period (days 1-11), there was a significant reduction in the odds of  
15  
16 8 transmission (Bayesian analysis (OR = 0.32, 95% Credible Interval = 0.11 to 0.83). In contrast, in  
17 9 Period 2 (day 12-29), the 95% credible interval of *Beta* coefficients for the treatment group includes  
18  
19 10 zero and therefore treatment was not effective in this period (Figure 2C, Supplementary Figure 2).  
20  
21  
22  
23

24 11 The effect of IFN $\beta$ -1 $\alpha$  on transmission was independent of household size (Supplementary Figure 3)  
25  
26  
27  
28  
29  
30

31 12  
32 13 To determine the effect of IFN $\beta$ -1 $\alpha$  treatment on viral shedding in those who became infected, we  
33  
34 14 examined the viral load trajectories in household contacts who became PCR positive after day 1. We  
35  
36 15 did not observe any difference in viral load trajectory in those treated with IFN $\beta$ -1 $\alpha$  compared to  
37  
38 16 controls (Figure 3A). Furthermore, there was no difference in peak viral load between treated  
39  
40 17 household contacts and controls who became infected (Figure 3B).  
41  
42  
43  
44  
45

46 18  
47 19 There were fifty-eight serious adverse events in index cases, twenty-seven hospitalizations due to  
48  
49 20 COVID-19 (25 in the treatment and 32 in the control arm) and was one death in the standard care arm  
50  
51 21 due to COVID-19 in an individual with significant co-morbidities. Twenty-six household contacts of  
52  
53 22 index cases were hospitalized, 10 in the treatment arm and 16 in the control arm, the difference was  
54  
55 23 not statistically significant.  
56  
57  
58  
59  
60



1  
2 1  
3  
4 2 **Discussion**

5  
6  
7 3 This prospective, household cluster randomized, ring prophylaxis trial demonstrated that pegylated  
8  
9 4 IFN $\beta$ -1 $\alpha$  may reduce household transmission of SARS-CoV-19. Pegylated IFN $\beta$ -1 $\alpha$  is an FDA  
10  
11 5 approved therapy for hepatitis C and multiple sclerosis for which the pharmacokinetics and safety  
12  
13 6 profile are well-characterized <sup>41</sup>. The use of this formulation allowed us to predict the likely duration  
14  
15 7 of activity of the three-dose regimen in order to cover the period of peak transmissibility of the virus.  
16  
17 8 Using a mobile medical team to administer doses at home optimized adherence to therapy and  
18  
19 9 allowed reasons for non-adherence and withdrawal to be accurately documented.  
20  
21  
22  
23

24 10  
25  
26 11 Although the intention to treat and per protocol analyses failed to demonstrate a significant effect on  
27  
28 12 primary outcomes, these analyses failed to account for index cases not shedding virus at  
29  
30 13 randomization nor an absence of eligible contacts within a household. Using biologically plausible  
31  
32 14 filters to define an at-risk population provided a better understanding of the effects of IFN $\beta$ -1 $\alpha$  than  
33  
34 15 intention to treat or per protocol analyses. These exploratory analyses that took account of the  
35  
36 16 likelihood that transmission could occur within a household provided a pragmatic assessment of the  
37  
38 17 effects of IFN $\beta$ -1 $\alpha$  therapy when given to household contacts as prophylaxis.  
39  
40  
41  
42  
43  
44 18

45  
46 19 The frequentist analysis of the at-risk populations indicated that *individuals* treated with IFN were less  
47  
48 20 likely to become infected than untreated individuals when exposed to virus with a relative risk  
49  
50 21 reduction of 23%. The Bayesian analysis revealed that the probability was 95% that transmission was  
51  
52 22 reduced in *households* randomized to IFN $\beta$ -1 $\alpha$  therapy. This effect of IFN $\beta$ -1 $\alpha$  on household  
53  
54 23 transmission was only significant during the active treatment period. This highlights the physiological  
55  
56  
57  
58  
59  
60

1  
2 1 importance of IFN $\beta$ -1 $\alpha$  as a sentinel molecule<sup>24</sup> and provides further evidence for post-exposure  
3  
4 2 prophylaxis with IFN $\beta$ -1 $\alpha$  as an antiviral strategy.  
5  
6

7 3  
8  
9 4 To our knowledge, only one previous study assessed ring prophylaxis in COVID-19. Labhardt et al  
10  
11 5 observed that a combination of lopinavir/ritonavir for 5 days as post-exposure prophylaxis was not  
12  
13 6 effective at preventing infection in close contacts of index cases<sup>42</sup>.  
14  
15  
16

17 7  
18  
19 8 The overall viral load trajectory we observed was very similar to that observed in a laboratory human  
20  
21 9 challenge experiment using wild-type SARS-CoV-2 virus in healthy volunteers<sup>43</sup>. Treatment with  
22  
23 10 IFN $\beta$ -1 $\alpha$  had no effect on viral load trajectory; therefore, reduced viral shedding by infected  
24  
25 11 individuals is unlikely to explain the protective effect on household transmission of IFN $\beta$ -1 $\alpha$  treatment  
26  
27 12 that we report. Given that treatment affected the probability of transmission only in the active  
28  
29 13 treatment phase and appears unrelated to viral load, we speculate that the observed effects of IFN $\beta$ -  
30  
31 14 1 $\alpha$  were direct through protection of the at-risk, exposed individual rather than indirectly through  
32  
33 15 effects on the index case. The ConCoRD-19 biorepository will allow further examination of the  
34  
35 16 mechanisms of action of IFN $\beta$ -1 $\alpha$  on resistance to infection.  
36  
37  
38

39 17  
40  
41 18 The study was undertaken prior to the emergence of the omicron strain of virus. We calculated the  
42  
43 19 sample size based upon known household transmission characteristics of the alpha strain which was  
44  
45 20 the dominant strain of the virus early in the pandemic. Simple hygiene measures and quarantine of  
46  
47 21 affected individuals within households could have contributed to lower rates of transmission than  
48  
49 22 expected. Together with a smaller number of eligible household contacts than anticipated from  
50  
51 23 census data, these factors may have reduced the power of the study for the primary outcomes. The  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 1 effect size observed in this study could be greater for variants with higher transmissibility such as the  
3  
4 2 Omicron strains that are now the dominant worldwide.  
5  
6  
7 3 Nonetheless, the beneficial biological effect of IFN $\beta$ -1 $\alpha$  treatment was evident in the at-risk  
8  
9 4 population and therefore, post-exposure or ring prophylaxis with IFN $\beta$ -1 $\alpha$  warrants further  
10  
11 5 investigation, particularly if additional virulent strains of SARS-CoV-2 emerge and for future pandemic  
12  
13 6 virus preparedness.  
14  
15  
16  
17 7

18  
19 8 In summary, although intention to treat and per protocol analyses failed to demonstrate significant  
20  
21 9 effects on primary outcomes, in a biologically defined, at risk population, the relative risk of infection  
22  
23 10 for an individual treated with pegylated IFN $\beta$ -1 $\alpha$  was reduced by 23.0%. Moreover, this is the first  
24  
25 11 study to demonstrate ring prophylaxis with pegylated IFN $\beta$ -1 $\alpha$  significantly reduces the probability of  
26  
27 12 household transmission of SARS-CoV-2. The effect of pegylated IFN $\beta$ -1 $\alpha$  was most obvious during the  
28  
29 13 active phase of treatment. In situations where there is emergence of a highly pathogenic and  
30  
31 14 transmissible mutant strain of SARS-CoV-2 despite high vaccination rates, or when there is a new viral  
32  
33 15 pandemic, IFN $\beta$ -1 $\alpha$  ring prophylaxis could be considered to reduce transmission in households or  
34  
35 16 amongst critical workers and vulnerable communities. Ring prophylaxis with therapies that can  
36  
37 17 interrupt transmission appears to be an effective strategy for highly contagious respiratory viruses.  
38  
39  
40  
41  
42  
43  
44 18

#### 46 19 **Funding.**

47 20 Biogen PTY Ltd. Supply of interferon as "Plegridy".  
48 21 The study was substantially funded by BHP Holdings Pty Ltd  
49 22

#### 51 23 **Authorship**

52 24 Authors, Castro-Rodriguez; Fish; Kollmann; Iturriaga, Karpievitch and Shannon contributed equally to  
53 25 the conduct of the study and manuscript as first authors.  
54 26

55 27 Authors, Tebbutt, Diego García-Huidobro, Perret, Borzutsky and Stick contributed equally to the  
56 28 conduct of the study and manuscript as senior authors.  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

Matthew Cooper (Telethon Kids Institute). Advice regarding protocol and establishment of randomization schedule.

Alexia Foti (Telethon Kids Institute). Collating, reviewing, and editing documents.

Zsuzsanna Hollander (PROOF Centre, Vancouver). Statistical advice and statistical analysis plan review.

Nat Eiffler (Telethon Kids Institute). Project management, protocol development, data management.

Jessica Meyer (University of Rochester). Assisting collation and formatting of tables and figures.

## References

1. Alizon S, Haim-Boukobza S, Foulongne V, et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. *Euro Surveill* 2021;26(28). DOI: 10.2807/1560-7917.ES.2021.26.28.2100573.
2. Mishra S, Mindermann S, Sharma M, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. *EClinicalMedicine* 2021;39:101064. DOI: 10.1016/j.eclinm.2021.101064.
3. Twohig K, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infectious Diseases* 2021. DOI: 10.1016/S1473-3099(21)00475-8.
4. Winger A, Caspari T. The Spike of Concern-The Novel Variants of SARS-CoV-2. *Viruses* 2021;13(6). DOI: 10.3390/v13061002.
5. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *medRxiv* 2021.
6. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet* 2022;399(10332):1303-1312. DOI: 10.1016/S0140-6736(22)00462-7.
7. Le Rutte E, Shattock A, Chitnis N, Kelly. SL, Penny M. Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden. *medRxiv*. Online server: Cold Spring Harbor Laboratory; 2021.
8. Centers for Disease Control and Prevention. Implementation of Mitigation Strategies for Communities with Local COVID-19 Transmission. CDC. May 23 2021.
9. Milne GJ, Xie S, Poklepovich D, O'Halloran D, Yap M, Whyatt D. A modelling analysis of the effectiveness of second wave COVID-19 response strategies in Australia. *Sci Rep* 2021;11(1):11958. DOI: 10.1038/s41598-021-91418-6.

- 1  
2 1 10. National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 38  
3  
4 2 Reporting period ending 28 March 2021. *Commun Dis Intell* (2018) 2021;45. DOI:  
5  
6 3 10.33321/cdi.2021.45.19.  
7  
8  
9 4 11. Houvessou GM, Souza TP, Silveira MFD. Lockdown-type containment measures for COVID-19  
10  
11 prevention and control: a descriptive ecological study with data from South Africa, Germany, Brazil,  
12 5  
13 Spain, United States, Italy and New Zealand, February - August 2020. *Epidemiol Serv Saude*  
14 6  
15 2021;30(1):e2020513. DOI: 10.1590/S1679-49742021000100025.  
16 7  
17  
18  
19 8 12. Conway SR, Lazarski CA, Field NE, et al. SARS-CoV-2-Specific T Cell Responses Are Stronger in  
20  
21 Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-  
22 9  
23 CoV-2 Infection. *Front Immunol* 2021;12:793197. DOI: 10.3389/fimmu.2021.793197.  
24 10  
25  
26 11 13. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. *JAMA*  
27  
28 2020;324(15):1495-1496. DOI: 10.1001/jama.2020.19759.  
29 12  
30  
31 13 14. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand  
32  
33 out in high-frequency shipping data. *PLoS One* 2021;16(4):e0248818. DOI:  
34 14  
35 10.1371/journal.pone.0248818.  
36 15  
37  
38 16 15. Chemen S, Gopalla YN. Lived experiences of older adults living in the community during the  
39  
40 COVID-19 lockdown - The case of mauritius. *J Aging Stud* 2021;57:100932. DOI:  
41 17  
42 10.1016/j.jaging.2021.100932.  
43 18  
44  
45 16. Mamun MA. Suicide and Suicidal Behaviors in the Context of COVID-19 Pandemic in Bangladesh:  
46  
47 A Systematic Review. *Psychol Res Behav Manag* 2021;14:695-704. DOI: 10.2147/PRBM.S315760.  
48 20  
49  
50 17. Callaway E. Beyond Omicron: what's next for COVID's viral evolution. *Nature* 2021;600(7888):204-  
51 21  
52 207. DOI: 10.1038/d41586-021-03619-8.  
53 22  
54  
55  
56  
57  
58  
59  
60

1  
2 1 18. Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon  $\beta$ -1b in treatment of severe COVID-  
3  
4 2 19: A randomized clinical trial. *Int Immunopharmacol* 2020;88:106903. (In eng). DOI:  
5  
6 3 10.1016/j.intimp.2020.106903.  
7  
8 4 19. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe  
9  
10 5 COVID-19: the COVIFERON randomized controlled trial. *Sci Rep* 2021;11(1):8059. (In eng). DOI:  
11  
12 6 10.1038/s41598-021-86859-y.  
13  
14 7 20. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and  
15  
16 8 Safety of Interferon  $\beta$ -1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother* 2020;64(9)  
17  
18 9 (In eng). DOI: 10.1128/aac.01061-20.  
19  
20 10 21. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with  
21  
22 11 COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Respir Med* 2021;9(5):498-510. (In  
23  
24 12 eng). DOI: 10.1016/s2213-2600(20)30566-x.  
25  
26 13 22. Meng Z, Wang T, Chen L, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to  
27  
28 14 Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. *Curr Top Med Chem*  
29  
30 15 2021;21(10):920-927. (In eng). DOI: 10.2174/1568026621666210429083050.  
31  
32 16 23. National Institutes of Health. Covid-19 Treatment Guidelines. In: Health NIH, ed.: United States  
33  
34 17 Government; 2021.  
35  
36 18 24. Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. *Front Immunol* 2018;9:2061.  
37  
38 19 DOI: 10.3389/fimmu.2018.02061.  
39  
40 20 25. Mazewski C, Perez RE, Fish EN, Plataniias LC. Type I Interferon (IFN)-Regulated Activation of  
41  
42 21 Canonical and Non-Canonical Signaling Pathways. *Front Immunol* 2020;11:606456. DOI:  
43  
44 22 10.3389/fimmu.2020.606456.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 1 26. Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. *Semin Immunol*  
3  
4 2 2019;43:101300. DOI: 10.1016/j.smim.2019.101300.  
5  
6  
7 3 27. World Health Organization. Informal consultation on the role of therapeutics in COVID-19  
8  
9 4 prophylaxis and post-exposure prophylaxis. . Worl Health Organization.  
10  
11  
12 5 28. Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? *Int J*  
13  
14 6 *Environ Res Public Health* 2020;17(11):3997. (In eng). DOI: 10.3390/ijerph17113997.  
15  
16  
17 7 29. Iturriaga C, Eiffler N, Aniba R, et al. A cluster randomized trial of interferon ss-1a for the reduction  
18  
19 8 of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19).  
20  
21 9 *BMC Infect Dis* 2021;21(1):814. DOI: 10.1186/s12879-021-06519-4.  
22  
23  
24 10 30. World Health Organization. Household transmission investigation protocol for 2019-novel  
25  
26 11 coronavirus (COVID-19) infection. Epidemiological protocol. Geneva: World Health Organization,  
27  
28 February 28th 2020 2020. (WHO/2019-nCoV/HHtransmission/2020.4)  
29 12  
30  
31 13 ([https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-](https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)  
32  
33 [novel-coronavirus-\(2019-ncov\)-infection](https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)).  
34 14  
35  
36 15 31. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally  
37  
38 16 effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during  
39  
40 17 interferon beta-1a (AVONEX) therapy. *Mult Scler* 2002;8(1):15-8. DOI: 10.1191/1352458502ms771sr.  
41  
42  
43 18 32. National Health and Medical Research Council. Guidance: Safety monitoring and reporting in  
44  
45 19 clinical trials involving therapeutic goods. Canberra: National Health and Medical Research Council;  
46  
47 20 2016.  
48  
49  
50  
51 21 33. Hofmeijer J, Anema PC, van der Tweel I. New algorithm for treatment allocation reduced  
52  
53 22 selection bias and loss of power in small trials. *J Clin Epidemiol* 2008;61(2):119-24. DOI:  
54  
55 23 10.1016/j.jclinepi.2007.04.002.  
56  
57  
58  
59  
60



- 1  
2 1 34. National Institute of Statistics. Chile Population and Housing Census 2017. Santiago, Chile:  
3  
4 2 National Institute of Statistics (Chile), 2021. ([http://ghdx.healthdata.org/record/chile-population-and-](http://ghdx.healthdata.org/record/chile-population-and-housing-census-2017)  
5  
6  
7 3 [housing-census-2017](http://ghdx.healthdata.org/record/chile-population-and-housing-census-2017)).
- 8  
9 4 35. World Health Organisation. Situation report - 50. Coronavirus disease 2019 (COVID-19) 50. World  
10  
11  
12 5 Health Organisation, 2020. ([https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)  
13  
14 6 [2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)).
- 15  
16 7 36. Yi B, Fen G, Cao D, et al. Epidemiological and clinical characteristics of 214 families with COVID-19  
17  
18  
19 8 in Wuhan, China. Int J Infect Dis 2021. DOI: 10.1016/j.ijid.2021.02.021.
- 20  
21 9 37. Curmei M, Ilyas A, Evans O, Steinhardt J. Constructing and adjusting estimates for household  
22  
23  
24 10 transmission of SARS-CoV-2 from prior studies, widespread-testing and contact-tracing data. Int J  
25  
26 11 Epidemiol 2021;50(5):1444-1457. DOI: 10.1093/ije/dyab108.
- 27  
28  
29 12 38. Bates DM, M.; Bolker, B.; Walker, S. Fitting linear mixed-effects models using lme4. Journal of  
30  
31 13 Statistical Software 2015;67(1):1-48. DOI: doi:10.18637/jss.v067.i01.
- 32  
33  
34 14 39. Goodrich B, Gabry J, Ali I, S. B. Bayesian applied regression modeling via Stan. R package version  
35  
36 15 2.21.1. rstanarm 2020 (<https://mc-stan.org/rstanarm>).
- 37  
38  
39 16 40. Brilleman SL, Crowther MJ, Moreno-Betancur M, Buros Novik J, Wolfe R. Joint longitudinal and  
40  
41 17 time-to-event models via Stan. StanCon 2018. 10-12 Jan 2018. Pacific Grove C, USA.  
42  
43 18 [https://github.com/stan-dev/stancon\\_talks/](https://github.com/stan-dev/stancon_talks/). Joint longitudinal and time-to-event models via Stan. .  
44  
45 19 StanCon 2018. Pacific Grove, CA, USA2018.
- 46  
47  
48 20 41. Hu X, Seddighzadeh A, Stecher S, et al. Pharmacokinetics, pharmacodynamics, and safety of  
49  
50  
51 21 peginterferon beta-1a in subjects with normal or impaired renal function. J Clin Pharmacol  
52  
53 22 2015;55(2):179-88. DOI: 10.1002/jcph.390.
- 54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 42. Labhardt ND, Smit M, Petignat I, et al. Post-exposure Lopinavir-Ritonavir Prophylaxis versus  
2 Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster  
3 Randomized Trial. *EClinicalMedicine* 2021;42:101188. DOI: 10.1016/j.eclinm.2021.101188.  
4 43. Ben K, Alex M, Mariya K, et al. *Nature Portfolio* 2022. DOI: 10.21203/rs.3.rs-1121993/v1.

Confidential: For Review

	Full study population		At-risk population	
	SOC (n = 565)	IFN (n = 607)	SOC (n = 246)	IFN (n = 293)
<b>Age (years)</b>				
Mean (SD)	35.0 (19.4)	33.2 (18.7)	29.2 (21.0)	29.0 (20.0)
<b>Sex</b>				
Female, n (%)	294 (52.0%)	323 (53.2%)	133 (54.1%)	171 (58.4%)
Male, n (%)	271 (48.0%)	284 (46.8%)	113 (45.9%)	122 (41.6%)
<b>Household occupants</b>				
Mean (SD)	4.10 (1.31)		4.28 (1.30)	4.86 (2.24)
<b>Fully vaccinated for SARS-CoV-2</b>				
No, n (%)	380 (67.3%)	438 (72.2%)	167 (67.9%)	217 (74.1%)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Yes, n (%)	103 (20.3%)	169 (27.8%)	79 (32.1%)	76 (25.9%)
<b>Cancer</b>				
No, n (%)	559 (98.9%)	598 (98.5%)	245 (99.6%)	290 (99.0%)
Yes, n (%)	5 (0.9%)	9 (1.5%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
<b>Diabetes</b>				
No, n (%)	542 (95.9%)	583 (96.0%)	238 (96.7%)	285 (97.3%)
Yes, n (%)	22 (3.9%)	24 (4.0%)	7 (2.8%)	8 (2.7%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
<b>Heart disease</b>				
No, n (%)	533 (94.3%)	578 (95.2%)	236 (95.9%)	281 (95.9%)
Yes, n (%)	31 (5.5%)	29 (4.8%)	9 (3.7%)	12 (4.1%)

Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
<b>Asthma</b>				
No, n (%)	524 (92.7%)	581 (95.7%)	230 (93.5%)	282 (96.2%)
Yes, n (%)	40 (7.1%)	26 (4.3%)	15 (6.1%)	11 (3.8%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
<b>Chronic lung disease</b>				
No, n (%)	564 (99.8%)	606 (99.8%)	245 (99.6%)	292 (99.7%)
Yes, n (%)	0 (0%)	1 (0.2%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
<b>Chronic kidney disease</b>				
No, n (%)	564 (99.8%)	604 (99.5%)	245 (99.6%)	292 (99.7%)
Yes, n (%)	0 (0%)	3 (0.5%)	0 (0%)	1 (0.3%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Chronic neurological disease</b>				
No, n (%)	562 (99.5%)	602 (99.2%)	245 (99.6%)	290 (99.0%)
Yes, n (%)	2 (0.4%)	5 (0.8%)	0 (0%)	3 (1.0%)
Missing, n (%)	1 (0.2%)	0 (0%)	1 (0.4%)	0 (0%)
<b>Smoker</b>				
No, n (%)	502 (88.8%)	519 (85.5%)	227 (92.3%)	255 (87.0%)
Yes, n (%)	63 (11.2%)	88 (14.5%)	19 (7.7%)	38 (13.0%)
Missing, n (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

1 **Table 1: Full study population demographics at baseline, and at-risk population demographics**  
2 **at baseline.**







Figure 1: CONSORT diagram describing participant screening, enrolment, randomisation, and analysis.

Confidential: Destroy when review is complete.

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276369>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

**A** All rights reserved. No reuse allowed without permission.




1 **Figure 2: Forrest plots describing primary and exploratory study outcomes. (A)** odds ratios  
 2 for index case populations in Primary Analysis 1 and associated sensitivity analyses, to  
 3 compare the probability of being SARS-COV-2 negative vs positive on study day 11 in  
 4 either treatment or standard of care arms. **(B)** odds ratios for household contact  
 5 populations in Primary Analysis 2 and associated sensitivity analyses, to compare the  
 6 probability of household contacts being SARS-CoV-2 negative vs positive on study day 11



medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276369>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 in either treatment or standard of care arms (IC) odds ratios for the exploratory frequentist  
2  
3  
4  
5  
6 and Bayesian analysis, to determine if IFN is associated with a reduction in the number of  
7  
8  
9 positive COVID-19 tests in household contacts across study period 1 (days 1-11) and  
10  
11  
12 study period 2 (days 12-29). Treatment with IFN is associated with a significant reduction  
13  
14  
15 in the odds of a positive COVID-19 test for all household contacts compared to standard of  
16  
17  
18 care; frequentist analysis ( $p = 0.033$ ; OR = 0.550, 95% CI = 0.364 to 0.989), Bayesian  
19  
20  
21 analysis (OR = 0.32, 95% CrI = 0.11 to 0.83). IC-INF = Infected case population (main  
22  
23  
24 analysis), IC-ITT = Index case – intention to treat population (sensitivity analysis 7.1.3.2),  
25  
26  
27 IC-PP = Index case – per protocol population (sensitivity analysis 7.1.3.3). EHC-ITT =  
28  
29  
30 Treatment-eligible household contact – intention to treat population (main analysis), HC =  
31  
32  
33 Household contact (eligible + non-eligible contacts) population (sensitivity analysis  
34  
35  
36 7.2.3.2), EHC-PP = Treatment-eligible household contact = per protocol population  
37  
38  
39  
40  
41  
42  
43  
44 (sensitivity analysis 7.2.3.3). \*  $p < 0.05$ .  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

medRxiv preprint doi: <https://doi.org/10.1101/2022.06.13.22276369>; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



1 **Figure 3: Log<sub>10</sub> viral load in study participants who test positive for COVID-19 after visit 1.**

2 **(A)** No significant difference in median viral load at each study visit between SOC and IFN

3 arms. **(B)** No significant difference in peak viral load between SOC and IFN arms. SOC =

4 standard of care arm, IFN = interferon arm, cp/mL = copies/mL. n = 57 (IFN) & n = 61

5 (SOC) participants per group.

## **Interferon Beta-1 $\alpha$ ring prophylaxis to reduce household transmission of SARS-CoV-2**

### **Supplementary Materials**

## Table of Contents

List of Study Investigators .....	4
Supplementary Methods .....	8
Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2.....	8
Viral load calculation.....	8
Populations used for analyses.....	9
Bayesian statistical analysis.....	9
Bayesian model.....	10
Computation of difference in probability of infection in IFN vs SOC arms .....	10
Supplementary Results.....	12
Bayesian analysis of infection reduction .....	12
Supplementary Figures .....	13
Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load .....	13
Supplementary Figure 2 Distribution of the difference in probability of infection between SOC and IFN arms by household size .....	14
Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and IFN arms .....	14
Supplementary Tables.....	15
Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial.....	17
Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.....	18

Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts .....	19
Supplementary Table 4: Study withdrawal reasons by treatment arm. ....	20
Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19. ....	21
Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis. ....	23
Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.....	24
Supplementary Table 8: Difference in probability of infection in each study period irrespective of household size.....	24
Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size.....	25
Supplementary Table 10: Number of contacts at each household size. ....	26
Supplementary References.....	27
Supplementary Appendices.....	28

## **List of Study Investigators**

### **Jose A. Castro-Rodriguez**

Department of Pediatric Pulmonology, School of Medicine, Pontificia Universidad Católica de Chile,  
Santiago, Chile

### **Eleanor N. Fish**

Department of Immunology, University of Toronto, Toronto, Canada

Toronto General Hospital Research Institute, University Health Network, Toronto, Canada

### **Tobias Kollman**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

### **Carolina Iturriaga**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia  
Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad  
Católica de Chile, Santiago, Chile

### **Yuliya Karpievitch**

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,  
Nedlands, Australia

School of Biomedical Sciences, University of Western Australia, Nedlands, Australia

### **Casey Shannon**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

### **Robert Balshaw**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Virginia Chen**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Samuel T. Montgomery**

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,

Nedlands, Australia

School of Population Health, Curtin University, Bentley, Australia

**Joseph Ho**

Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,

Nedlands, Australia

**Rad Aniba**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Rym Ben Othman**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Francisca Gidi-Yunge**

School of Dentistry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

**Lucy Hartnell**

Telethon Kids Institute, University of Western Australia, Nedlands, Australia

**Guillermo Pérez-Mateluna**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia  
Universidad Católica De Chile, Santiago, Chile

**Marcela Urzúa**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia  
Universidad Católica De Chile, Santiago, Chile

**Scott Tebbit**

Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, Canada

Centre for Heart Lung Innovation, Providence Health, St Paul's Hospital, Vancouver, Canada

**Diego García-Huidobro**

Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile,  
Santiago, Chile

Department of Family Medicine and Community Health, University of Minnesota, United States of  
America

**Cecilia Perret**

Department of Pediatric Infectious Diseases and Immunology , School of Medicine, Pontificia  
Universidad Católica de Chile, Santiago, Chile

**Arturo Borzutzky**

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia  
Universidad Católica de Chile, Santiago, Chile

Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad  
Católica de Chile, Santiago, Chile

**Stephen M. Stick**



Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia,  
Nedlands, Australia

Perth Children's Hospital, Nedlands, Australia

## Supplementary Methods

### Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for SARS-CoV-2

RNA extraction and RT-qPCR for SARS-CoV-2 detection was performed at the Infectiology and Molecular Virology Laboratory, Red Salud UC Christus, Santiago, Chile. RNA was extracted in parallel from saliva using the MagBind RNA extraction kit (#GN7101907, Maccura Biotechnology, Rockville, MD, USA) with the Auto-Pure 32A Nucleic Purification System (Maccura Biotechnology, Rockville, MD, USA), and using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Real-time PCR amplification was performed using the LightMix Modular Wuhan CoV RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) targeting the RNA-dependent RNA polymerase (RdRP) gene, targeting SARS-CoV-2, but not other SARS-like viruses (CoVNL63, CoV229E, HKE, OC43, MERS), with a positive control containing three separate diagnostic targets (E gene, N gene, RdRP). The reverse transcription and PCR processes occur in a single step in a real-time thermocycler (Lightcycler 480 II, Roche, Berlin, DE) with an analytical sensitivity of 10.6 copies per reaction. A cycle threshold (Ct) value of  $\leq 37$  was considered positive for SARS-CoV-2.

### Viral load calculation

The viral load of SARS-CoV-2 detected in saliva was calculated using a standard curve. A commercial SARS-CoV-2 standard (#COV019, Exact Diagnostics, Fort Worth, TX, USA) at a concentration of 200,000 copies per mL (cp/mL) was extracted in triplicate using the RNA/DNA Purification Magnetic Bead Kit (#DA0630, DaAnGene, Guangzhou, CN) with the Smart32 Nucleic Acid Extraction Instrument (DaAnGene, Guangzhou, CN) according to manufacturer specifications. Following extraction, serial dilutions (1:10; 200,000cp/mL to 20cp/mL & 1:5; 200,000cp/mL to 64cp/mL) were used in triplicate for reverse transcription and RT-qPCR using the LightMix Modular Wuhan CoV

RdRP-gene kit (#53-0777-96, TIB MolBiol, Roche, Berlin, DE) with the Lightcycler 480 II thermocycler (Roche, Berlin, DE), resulting in 9 replicates at each concentration. SARS-CoV-2 was detectable in all nine replicates at 200,000cp/mL, 40,000cp/mL, 20,000cp/mL, 8,000cp/mL, 2000cp/mL, and 1,600cp/mL, and a standard curve was generated using the mean Ct values for these concentrations (Supplementary Figure 1) to calculate SARS-CoV-2 viral load in samples of unknown titre, resulting in a lower limit of quantification of 1,600cp/mL.

### **Populations used for analyses**

Participants were excluded for analysis as outlined in the statistical analysis plan, or as outlined in the exploratory analysis (Supplementary Appendix B). Total households and participants excluded and used in each population are described in Supplementary Table 6. Briefly, participants were excluded from the populations used in the primary analyses (IC-INF, IC-ITT, EHC-ITT, HC) if the study visit was not performed, or was performed outside the  $\pm 1$  day window either side of the scheduled visit date (Statistical Analysis Plan 6.5). Participants who didn't complete the full course of the treatment were excluded from the Per Protocol populations used in the primary analyses (IC-PP, EHC-PP). In the exploratory analysis, whole households were excluded if the index case was SARS-CoV-2 negative via salivary PCR at study days 1 & 6, and if there were no SARS-CoV-2 negative eligible or ineligible contacts in the household at study day 1. Participants were then excluded from the exploratory analysis if they were SARS-CoV-2 positive via salivary PCR at study day 1. Participants were further excluded from the Bayesian analysis where household size was greater than 7, as these household sizes were unable to be modelled using Bayesian modelling.

### **Bayesian statistical analysis**

Bayesian analysis was included in the original statistical analysis plan. The goal was to test the null hypothesis that treatment of household contacts with IFN $\beta$ -1 $\alpha$  does not reduce the probability of transmission from an infected index case to household contacts. As outlined in the analysis plan, we

used data to develop a data generating process governed by probabilities that a household contact of an index case would test positive to COVID-19, and non-informative prior was used.

### **Bayesian model**

A generalized linear model with mixed effects was developed to estimate the probability of infection for each contact. A `stan_glm` with binomial logit function from the `rstanarm` package (1) was run using R (version 4.1.1) to obtain Beta coefficients for 4,000 simulated samples to estimate the probability of infection using the following model:

$$p_{cr} \sim (1 | index) + vacc + viral + infected + eligible + sex + age + arm$$

where: *p<sub>cr</sub>*: binary COVID-19 test result, *index*: index case in the household – treated as a random effect, *vacc*: number of vaccinated household members, *viral*: log<sub>10</sub> viral load of the index case at the beginning of the period, *infected*: number of COVID-19 positive household members at the beginning of the period, *eligible*: whether the household contact was eligible for treatment, *sex*: sex of the household contact, *age*: age of the household contact, and *arm*: study arm (i.e. SOC/IFN) of the household were the fixed explanatory variables.

The features of the model were the same as the exploratory frequentist analysis, with the exception of adding the treatment period as a feature. Instead, the Bayesian analysis split the data into two periods (Period 1: study days 1–11, Period 2: study days 12–29) with analysis conducted separately. For period 2, COVID-19 positivity at day 11 was used to determine COVID-19 positive household members at the beginning of the period. The population used for analysis was the same as the “At-risk” population used in the exploratory frequentist analysis (Supplementary Table 6), with the additional exclusion of participants in households with a size larger than 8.

### **Computation of difference in probability of infection in IFN vs SOC arms**

In each simulation, we obtained a PCR outcome for each contact from the Bayesian model by applying the `posterior_predict` function in the `rstanarm` package to the observed data (1). We further computed the percent of infections in each treatment arm irrespective of household size (Supplementary Table 8) and for each household size (Supplementary Table 9). Furthermore, we computed the difference in probability of infection by subtracting the probability of infection in IFN arm from the probability of infection in SOC arm. As a results, we obtained 4000 differences (irrespective of household size) and 4000 differences for each household size

Significance of the treatment effect was determined by 95% credible interval (CrI) for the treatment Beta coefficient. If 0 was included in the CrI, the effect of treatment group was considered not significant. Average Beta coefficient and odds ratio for the effect of the IFN treatment as compared to SOC were computed in each study period. The average odds ratio of being infected with SARS-CoV-2 on IFN treatment vs. SOC was calculated by exponentiating the values of the average of the coefficients (Supplementary Table 7).

## Supplementary Results

### Bayesian analysis of infection reduction


Treatment with IFN had a significant effect in study period 1 as the 95% CrI for treatment coefficient did not include zero (Supplementary Table 7). However, IFN treatment did not have a significant effect in period 2 as the 95% CrI did include zero (Supplementary Table 7).

In study period 1, there was 95% probability of infection reduction between 0.9% to 15.9% due to the IFN treatment, with 8.5% median and mean infection reduction (Supplementary Table 8). In study period 2, there are 95% probability of infection reduction -6.7% to 4.8% due to the IFN treatment, with -9% of median and mean of infection reduction (Supplementary Table 8).


When we stratified the infection reduction by household size, only households' size 3 and 4 in period 1 had a 95% CrI without zero (Supplementary Table 9).

As the distribution of Bayesian estimated differences in probabilities of infection in study period 1 is centred to the right of 0 (Supplementary Figure 3A), IFN treatment had an effect on reducing SARS-CoV-2 transmission within households. However, as the distribution in study period 2 is centred around 0, it suggests IFN has no effect on SARS-CoV-2 transmission within households (Supplementary Figure 3B).


## Supplementary Figures



**Supplementary Figure 1: Standard curve for calculation of SARS-CoV-2 viral load.** Mean cycle threshold (Ct) values are plotted on the y-axis, and log<sub>10</sub> SARS-CoV-2 copies per mL (cp/mL) are plotted on the x-axis. Linear regression resulted in an R<sup>2</sup> value of 0.9972, to fit the equation  $y = -3.719x + 48.83$ .



**Supplementary Figure 2: Distribution of the difference in probability of infection between SOC and IFN arms. (A)** Distribution in study period 1, and **(B)** Distribution in study period 2. Vertical black line represents zero difference in probability of infection between SOC and IFN arms.



**Supplementary Figure 3: Distribution of the difference in probability of infection between SOC and IFN arms by household size. (A)** Distribution in study period 1, and **(B)** Distribution in study period 2. Vertical dashed black line represents zero difference in probability of infection between SOC and IFN arms.



## Supplementary Tables

<b>Primary Objectives</b>	<b>Outcome &amp; Outcome Measure</b>
To determine whether IFN $\beta$ -1 $\alpha$ treatment reduces the proportion of infected cases shedding SARS-CoV-2 at day 11 after randomization.	The proportion of index cases shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm
To determine whether IFN $\beta$ -1 $\alpha$ treatment reduces the incidence of SARS-CoV-2 transmission from index cases to treatment-eligible household contacts, as measured by any positive upper airway infection evidenced by real-time Polymerase Chain Reaction (RT-PCR), in contacts at day 11 after randomization.	The proportion of household contacts shedding SARS-CoV-2 at day 11 in the active arm compared to the standard of care arm
<b>Secondary Objectives</b>	<b>Outcome &amp; Outcome Measure</b>
To determine whether in index cases infected with SARS-CoV-2, IFN $\beta$ -1 $\alpha$ treatment compared with standard of care reduces the duration of SARS-CoV-2 upper airway virus shedding over 28 days following randomization.	Duration (in days) of SARS-CoV-2 measured by PCR of samples taken on study days 1, 6, 11, 16, 21, and 29

<p>To determine whether IFN <math>\beta</math>-1<math>\alpha</math> treatment affects the incidence of SARS-CoV-2 upper airway infection or serological conversion by study day 29 in household contacts.</p>	<p>Number of household contacts of participants in the IFN arm with positive upper airway PCR compared to that in the standard of care arm at day 1 &amp; 11, and seroconversion (IgM) over the study period up to day 29</p>
<p>To determine whether IFN <math>\beta</math>-1<math>\alpha</math> treatment compared with standard of care reduces the proportion of infected cases that require hospital admission or die due to COVID-19</p>	<p>The proportion of infected cases in the active arm that are hospitalized or die due to COVID-19, as compared to the proportion in the standard of care arm</p>
<p>To determine the safety of IFN <math>\beta</math>-1<math>\alpha</math> in the treatment and prevention of SARS-CoV-2 infection</p>	<p>Incidence and severity of reported adverse events in the active arm compared to the standard of care arm</p>

**Exploratory Objectives**

**Biological samples and associated data will be stored for later access for ethically approved research relevant to the exploratory objectives**

- Assess the impact of participant demographic and clinical metadata on the viral transmission dynamics and response to IFN  $\beta$ -1 $\alpha$  in the household using unbiased systems epidemiology
- Assess the impact of host biology on the viral transmission dynamics and response to IFN  $\beta$ -1 $\alpha$  in the household using unbiased systems biology
- Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN  $\beta$ -1 $\alpha$  intervention

---

Integrate the demographic and clinical data with the biological host data to decipher potential interactions relevant to outcome of infection or exposure, as well as response to IFN  $\beta$ -1 $\alpha$  intervention

---

Estimate the secondary infection rate, serial interval, incubation period, duration of infectiousness, duration of detected shedding

---

*Individual level:* SARS-CoV-2 shedding as determined by PCR of upper respiratory samples analyzed as a function of time of exposure relative to the start of the intervention

---

*Household/Community level:* While each study arm will be assessed independently of each other as secondary objectives, we will assess the impact of any intervention on the entire household. When demographic and/or biological variables

---

Host immune response (anti SARS-CoV-2 antibodies, blood cytokines and chemokines), as well as blood and nasal mucosal host response (including but not limited to transcriptomics, metabolomics, proteomics, and epigenomics) to IFN  $\beta$ -1 $\alpha$  intervention, SARS-CoV-2 infection and their interaction

---

**Supplementary Table 1: Primary, secondary, and exploratory outcomes for the Containing Coronavirus Disease-19 clinical trial**

	<b>Visit 1</b>	<b>Visit 2</b>	<b>Visit 3</b>	<b>Visit 4</b>	<b>Visit 5</b>	<b>Visit 6</b>	<b>Extra Visit – Suspected COVID-19</b>
<b>Study Day</b>	<b>1</b> <b>Dose 1</b>	<b>6</b> <b>Dose 2</b>	<b>11</b> <b>Dose 3</b>	<b>16</b>	<b>21</b>	<b>29</b>	
<b>Blood Samples</b>							
Complete Blood count/ ESR	X					X	X
SARS-CoV-2 antibodies (IgGAM)	X					X	
Study sample 1	X	X	X			X	X
Study sample 2	X	X	X			X	X
Study sample 3	X	X	X			X	X
<b>Airway samples</b>							
Nasal brush	X						
Nasal lining fluid	X	X	X				
Airway Swab for COVID-19 diagnosis							X
<b>Saliva Samples</b>							
Saliva	X	X	X	X	X	X	X

**Supplementary Table 2: Schedule of laboratory assessments for index cases and treatment eligible household contacts.**

	<b>Visit 1</b>	<b>Visit 2</b>	<b>Visit 3</b>	<b>Visit 4</b>	<b>Visit 5</b>	<b>Visit 6</b>	<b>Extra Visit – Suspected COVID-19</b>
<b>Study Day</b>	<b>1</b> <b>Dose 1</b>	<b>6</b> <b>Dose 2</b>	<b>11</b> <b>Dose 3</b>	<b>16</b>	<b>21</b>	<b>29</b>	
<b>Blood Samples</b>							
Complete Blood count/ ESR							<b>X</b>
SARS-CoV-2 antibodies (IgGAM)						<b>X</b>	
Study sample 1						<b>X</b>	<b>X</b>
Study sample 2						<b>X</b>	<b>X</b>
Study sample 3						<b>X</b>	<b>X</b>
<b>Airway samples</b>							
Nasal brush	<b>X</b>						
Nasal lining fluid	<b>X</b>	<b>X</b>	<b>X</b>				
Airway Swab for COVID-19 diagnosis							<b>X</b>
<b>Saliva Samples</b>							
Saliva	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>

**Supplementary Table 3: Schedule of laboratory assessments for treatment ineligible household contacts.**

Interferon arm										Standard of Care arm									
Withdrawal reason	Days since enrolment									Withdrawal reason	Days since enrolment								
	3	4	5	10	11	14	15	21	28		3	4	5	10	11	14	15	25	28
Family withdrew	0	0	5	0	0	2	0	0	0	Family withdrew	0	0	2	0	0	0	0	0	0
Interpersonal problems	0	0	3	0	0	0	0	0	0	Interpersonal problems	0	4	0	0	0	0	0	0	0
Lack of time	0	1	0	0	0	0	0	0	0	Lack of time	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	Other	0	0	1	0	0	0	0	0	0
Parental decision	0	0	2	0	0	0	0	0	0	Parental decision	0	0	0	0	0	0	0	0	0
Poor health	0	0	1	0	0	1	0	0	0	Poor health	0	0	0	0	0	0	0	0	0
Sample collection problems	0	0	0	0	0	0	0	0	0	Sample collection problems	0	0	1	0	0	0	0	0	0
Side effects of drug	0	0	0	0	0	2	0	0	0	Side effects of drug	0	0	0	0	0	0	0	0	0
Uninterested	0	0	0	1	0	0	0	0	1	Uninterested	0	0	0	0	0	0	0	0	0
Unspecified	4	3	1	2	1	0	0	0	0	Unspecified	0	1	3	0	0	0	1	5	0
Work commitments	0	0	2	2	0	0	0	0	0	Work commitments	0	0	0	0	0	0	0	0	0

**Supplementary Table 4: Study withdrawal reasons by treatment arm.**

**Reasons for exclusion from ConCorD-19 during screening Participants (n)**

Unable to be contacted	736
Days of symptoms > 5	777
Asymptomatic	306
Isolating from household contacts	219
Hospitalized	177
Confirmation of COVID-19 took longer than 72 hours	35
Deceased	2
Ineligible medical condition or treatment	67
Less than 18 years old	54
Pregnant, or plans on becoming pregnant	32
Previously infected with COVID-19	36
Greater than 80 years old	3
All eligible household contacts currently infected	514
Does not live with eligible household contact	412
Not the first infection in the household	392
Does not live in the Santiago metropolitan area	20
<b>Reasons for not participating in ConCorD-19</b>	
Index case declined	835
Eligible household contact declined	196
<b>Total</b>	<b>4813</b>

**Supplementary Table 5: Reasons for exclusion from study participation during screening and reasons for declined participation following invitation to participate in ConCorD-19.**

Analyses outlined in SAP		Exclusions		Participants (n) included for analyses			
Analysis	Population	Reason	Participants (n)		IFN	SOC	
	Full study population			<b>IC</b>	172	169	
				<b>EHC</b>	177	165	
					<b>CP-HC</b>	80	81
					<b>IHC</b>	178	150
Primary 1 - Main	IC-INF at day 11	No visit	22	<b>IC</b>	159	164	
		Visit outside window	3	<b>CP-HC</b>	69	76	
Primary 1 – Sensitivity 1	IC-ITT at day 11	No visit	12	<b>IC</b>	159	164	
		Visit outside window	2				
Primary 1 – Sensitivity 2	IC-PP at day 11	No visit or protocol deviation	26	<b>IC</b>	146	164	
		Visit outside window	1				
Primary 2 – Main	EHC-ITT at day 11	No visit	20	<b>EHC</b>	166	156	
Primary 2 – Sensitivity 1	HC at day 11	No visit	37	<b>EHC</b>	166	156	
				<b>IHC</b>	168	143	



Primary 2 – Sensitivity 2	EHC-PP at day 11	No visit or protocol deviation	30		<b>EHC</b>	156	156
<b>Exploratory Analyses</b>		<b>Exclusions</b>					
<b>Analysis</b>	<b>Population</b>	<b>Reason</b>	<b>Households (n)</b>	<b>Participants (n)</b>			
Frequentist	Household contacts, COVID- 19 negative at study day 1	COVID-negative index case	33		<b>EHC</b>	164	142
		No household contacts at risk	49				
	Household contact COVID positive		43		<b>IHC</b>	129	104
Bayesian	Frequentist population, household size $\leq 7$	Household size $> 7$	5	61	<b>EHC</b>	152	139
					<b>IHC</b>	113	104

**Supplementary Table 6: Study populations used for analysis, and reasons for exclusion from analysis.** IC: index case, EHC: Treatment eligible household contacts, CP-HC: COVID-19 positive household contacts, IHC: Treatment ineligible household contacts, IC-INF: IC & CP-HC, IC-ITT: Index case – intention to treat population, IC-PP: Index case – per protocol population, EHC-ITT: Treatment eligible household contacts – intention to treat population, HC: EHC and IHC, EHC-PP: Treatment eligible household contact – per protocol population.

Study period	Mean	Standard Deviation	Lower limit (2.5%)	Upper limit (97.5%)
1	-1.17	0.52	-2.23	-0.19
2	0.27	0.55	-0.80	1.36

**Odds ratio for treatment with IFN**

**95% Credible Intervals**

Study period	Mean	Standard Deviation	Lower limit (2.5%)	Upper limit (97.5%)
1	0.32	1.68	0.11	0.83
2	1.31	1.73	0.45	3.90

**Supplementary Table 7: Bayesian estimated beta coefficients and odds ratio for treatment with IFN, with average values and 95% credible intervals.**

Study period	2.5%	25%	50%	Mean	75%	97.5%
1	0.009	0.059	0.085	0.085	0.110	0.159
2	-0.067	-0.028	-0.009	-0.009	0.010	0.048

**Supplementary Table 8: Difference in probability of infection in each study period**

**irrespective of household size.** Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

Study period	Household size	2.5%	25%	50%	Mean	75%	97.5%
1	2	-0.143	0.000	0.286	0.053	0.143	0.286
1	3	0.000	0.092	0.276	0.139	0.184	0.276
1	4	0.003	0.087	0.249	0.128	0.170	0.249

1	6	-0.120	0.030	0.326	0.103	0.189	0.326
1	7	-0.231	-0.077	0.308	0.024	0.077	0.308
2	2	-0.118	-0.059	0.075	-0.008	0.000	0.075
2	3	-0.085	-0.021	0.090	0.001	0.028	0.090
2	4	-0.130	-0.068	0.059	-0.037	-0.006	0.059
2	5	-0.128	-0.052	0.103	-0.013	0.027	0.103
2	6	-0.129	-0.015	0.254	0.059	0.117	0.254
2	7	-0.154	0.000	0.154	0.016	0.077	0.154

**Supplementary Table 9: Difference in probability of infection in each study period, stratifying by household size.** Data is the mean, median, and 95% CrI difference in probability of infection in each study period, computed as probability of infection in the SOC arm minus the probability of infection in the IFN arm.

Household size	Number of households	Eligible contacts	Eligible contacts
2	42	42	0
3	61	64	27
4	80	84	89
5	46	58	59
6	19	29	30
7	6	14	12

**Supplementary Table 10: Number of contacts at each household size.**

## Supplementary References

1. Goodrich B GJ, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.21.3 ed2022.

## Supplementary Appendices